LilyR
Nov 21, 6:30 PM
$SLS Bidding war , 4 Big Pharma Suitors
1️⃣ Merck (
$MRK): Already ran clinical combos of GPS + Keytruda (showing strong survival data in ovarian cancer). With Keytruda’s 2028 patent cliff looming, an off-the-shelf vaccine is the ultimate combo shield.
2️⃣ Bristol Myers Squibb (
$BMY): The undisputed king of hematology (Onureg, Reblozyl) + facing Opdivo’s patent cliff. GPS fits straight into BMY’s existing AML salesforce on Day 1 while boosting Opdivo in solid tumors.
3️⃣ AbbVie (
$ABBV): Venclexta dominates frontline AML induction—GPS is the logical next step for post-remission maintenance, creating a complete end-to-end AML franchise (plus CDK9 inhibitor SLS009 as a bonus).
4️⃣ AstraZeneca (
$AZN) / Roche: Both are aggressively expanding PD-L1s (Imfinzi / Tecentriq) into early-stage/adjuvant settings where GPS shines by clearing minimal residual disease.
Off-the-shelf + Phase 3 validated + multi-tumor scalability = prime M&A tension.
4 replies